Lumos Pharma, Inc. announced the appointment of An van Es-Johansson, M.D., to its board of directors, effective immediately, where she will serve as a member of the Nominating and Governance Committee. Dr. van Es-Johansson will succeed Emmett Cunningham who is resigning his board position to focus on other professional obligations in his managerial role at Blackstone Life Sciences. Dr. An van Es-Johansson is the Chief Medical Officer and Head of Development for AlzeCure Pharma and will transition to a Senior Advisor role on March 1, 2021.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA, INC. 
